Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation (NQ: VCEL )

56.71 -0.55 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation

< Previous 1 2 3 4 5 Next >
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Vericel Reports Third Quarter 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Earnings Preview For Vericel
Via Benzinga
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
From Vericel Corporation
Via GlobeNewswire
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
Via Benzinga
Expert Ratings For Vericel
Via Benzinga
The Latest Analyst Ratings For Vericel
Via Benzinga
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
From Vericel Corporation
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
Via Benzinga
Critical Insights From Vericel Analyst Ratings: What You Need To Know
Via Benzinga
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Vericel Reports Second Quarter 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
From Vericel Corporation
Via GlobeNewswire
Analyst Scoreboard: 5 Ratings For Vericel
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Vericel
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
The 3 Highest-Rated Medical Stocks You Can Buy Today
Are you looking for highly-rated medical stocks? These three contenders are offering substantial growth over the long term. 
Via InvestorPlace
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
From Vericel Corporation
Via GlobeNewswire
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
From Vericel Corporation
Via GlobeNewswire
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.